Wilcock Louisa K, Francis James N, Durham Stephen R
Upper Respiratory Medicine, Imperial College, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK.
Immunol Allergy Clin North Am. 2006 May;26(2):333-47, viii-ix. doi: 10.1016/j.iac.2006.02.004.
IgE-facilitated allergen presentation (FAP) is an important pathogenic mechanism in allergic disease and represents a potential therapeutic target. Allergen immunotherapy is a highly effective therapy, particularly in patients with seasonal pollinosis who fail to respond to usual pharmacotherapy. Allergen immunotherapy induces "blocking" IgG antibodies that are detectable in serum and have been shown to inhibit IgE-FAP in vitro. This review summarizes the main components involved in IgE-FAP and the potential value of a validated functional assay of serum inhibitory antibodies for IgE-FAP for monitoring the clinical response to immunotherapy.
IgE介导的变应原呈递（FAP）是变应性疾病的一种重要致病机制，也是一个潜在的治疗靶点。变应原免疫疗法是一种高效的治疗方法，尤其适用于对常规药物治疗无效的季节性花粉症患者。变应原免疫疗法可诱导血清中可检测到的“阻断性”IgG抗体，并且已证实在体外其可抑制IgE-FAP。本综述总结了IgE-FAP涉及的主要成分，以及用于监测免疫治疗临床反应的经验证的IgE-FAP血清抑制性抗体功能检测的潜在价值。
